Adherence to mass drug administration with dihydroartemisinin-piperaquine and plasmodium falciparum clearance in Southern Province, Zambia

American Journal of Tropical Medicine and Hygiene

Volumn 103, Issue 2, 2020, Pages 37-45

  Finn, Timothy P ^a   Porter, Travis R ^a   Moonga, Hawela ^b   Silumbe, Kafula ^c   Daniels, Rachel F ^d,e   Volkman, Sarah K ^d,e,f   Yukich, Joshua O ^a   Keating, Joseph ^a   Bennett, Adam ^g   Steketee, Richard W ^h   Miller, John M ^c   Eisele, Thomas P ^a  

^a TULANE UNIVERSITY   (United States)

^b MINISTRY OF HEALTH   (Zambia)

^c Malaria Control and Evaluation Partnership in Africa (MACEPA)   (Zambia)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f SIMMONS COLLEGE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ARTICLE; ASEXUAL REPRODUCTION; BLOOD SMEAR; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DENSITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GAMETOCYTE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MASS DRUG ADMINISTRATION; NONHUMAN; PARASITE CLEARANCE; PARASITE DENSITY; PARASITEMIA; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; POPULATION RESEARCH; PRESCHOOL CHILD; UNSPECIFIED SIDE EFFECT; ZAMBIA; COMBINATION DRUG THERAPY; DISEASE ERADICATION; DRUG EFFECT; FAMILY SIZE; INTERVIEW; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DISEASE ERADICATION; DRUG THERAPY, COMBINATION; FAMILY CHARACTERISTICS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALARIA, FALCIPARUM; MALE; MASS DRUG ADMINISTRATION; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PLASMODIUM FALCIPARUM; QUINOLINES; ZAMBIA;

EID: 85089301601     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.19-0667     Document Type: Article

References (38)

1. Zambia Ministry of Health, 2012. National Malaria Control Programme Strategic Plan for FY 2011-2015: Consolidating Malaria Gains for Impact. Lusaka, Zambia: Ministry of Health, National Malaria Control Programme.
2. Eisele TP et al., 2015. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials 16: 347.
3. Yukich JO et al., 2020. Cost-effectiveness of focal mass drug administration and mass drug administration with dihydroartemisinin-piperaquine for malaria prevention in Southern Province, Zambia: results of a community-randomized control trial. Am J Trop Med Hyg 103 (Suppl 2): 46-53.
4. Mayxay M et al., 2006. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Trop Med Int Health 11: 1157-1165.
5. Ashley EA et al., 2005. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41: 425-432.
6. Trung TN, Tan B, Van Phuc D, Song J, 2009. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med 15: 189-192.
7. Ogutu BR et al., 2014. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J 13: 33.
8. Sylla K et al., 2013. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis 13: 598.
9. Song J et al., 2011. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 10: 231.
10. Zwang J et al., 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4: e6358.
11. Four Artemisinin-Based Combinations (4ABC) Study Group, 2011. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 8: e1001119.
12. Sawa P et al., 2013. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 207: 1637-1645.
13. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D, 2014. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 1: 1-160.
14. World Health Organization, 2018. Status Report on Artemisinin Resistance and ACT Efficacy (August 2018). Available at: http://www.who.int/malaria/publications/atoz/artemisinin-resistanceaugust2018/en/. Accessed November 29, 2018.
15. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D, 2014. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One 9: e84555.
16. Krentel A, Fischer PU, Weil GJ, 2013. A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis 7: e2447.
17. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP, 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8: 253.
18. Gosling RD, Okell L, Mosha J, Chandramohan D, 2011. The role of antimalarial treatment in the elimination of malaria. Clin Micro-biol Infect 17: 1617-1623.
19. Shuford KV, Turner HC, Anderson RM, 2016. Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasit Vectors 9: 29.
20. Yeung S, White NJ, 2005. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health 10: 121-138.
21. Eisele TP et al., 2016. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis 214: 1831-1839.
22. Daniels R et al., 2008. A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking. Malar J 7: 223.
23. Tanner M, Lengeler C, Lorenz N, 1993. From the efficacy of disease control tools to community effectiveness. Trans R Soc Trop Med Hyg 87: 518-523.
24. Littrell M, Miller JM, Ndhlovu M, Hamainza B, Hawela M, Kamuliwo M, Hamer DH, Steketee RW, 2013. Documenting malaria case management coverage in Zambia: a systems effectiveness approach. Malar J 12: 371.
25. Eisele TP et al., 2020. Impact of four rounds of mass drug administration with dihydroartemisinin-piperaquine implemented in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 7-18.
26. Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM, 2014. Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malar J 13: 138.
27. Nikolov M, Bever CA, Upfill-Brown A, Hamainza B, Miller JM, Eckhoff PA, Wenger EA, Gerardin J, 2016. Malaria elimination campaigns in the Lake Kariba region of Zambia: a spatial dynamical model. PLoS Comput Biol 12: e1005192.
28. Stepniewska K, White NJ, 2006. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5: 127.
29. World Health Organization, 2016. Status Report on Artemisinin and ACT Resistance (October 2016). Available at: http://www.who.int/malaria/publications/atoz/update-artemisinin-resistanceoctober2016/en/. Accessed November 1, 2017.
30. Muhindo MK et al., 2014. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J 13: 32.
31. Juliano JJ, Ariey F, Sem R, Tangpukdee N, Krudsood S, Olson C, Looareesuwan S, Rogers WO, Wongsrichanalai C, Meshnick SR, 2009. Misclassification of drug failures in Plasmodium falciparum clinical trials in southeast Asia. J Infect Dis 200: 624-628.
32. Juliano JJ, Gadalla N, Sutherland CJ, Meshnick SR, 2010. The perils of PCR: can we accurately 'correct' antimalarial trials? Trends Parasitol 26: 119-124.
33. Budge PJ, Sognikin E, Akosa A, Mathieu EM, Deming M, 2010. Accuracy of coverage survey recall following an integrated mass drug administration for lymphatic filariasis, schistosomiasis, and soil-transmitted helminthiasis. PLoS Negl Trop Dis 10: e0004358.
34. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Available at: https://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/. Accessed November 28, 2018.
35. Chishimba S et al., 2020. Prevalence of Plasmodium falciparum and non-falciparum infections by photo-induced electron transfer-PCR in a longitudinal cohort of individuals enrolled in a mass drug administration trial in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 82-89.
36. Kalinowski P, Fidler F, 2010. Interpreting significance: the differences between statistical significance, effect size, and practical importance. Newborn Infant Nurs Rev 10: 50-54.
37. Kühberger A, Fritz A, Lermer E, Scherndl T, 2015. The significance fallacy in inferential statistics. BMC Res Notes 8: 84.
38. Yakasai AM, Hamza M, Dalhat MM, Bello M, Gadanya MA, Yaqub ZM, Ibrahim DA, Hassan-Hanga F, 2015. Adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria: a systematic review and meta-analysis. J Trop Med 2015: 189232.